PCI 3.06.26
Wallonia
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Upcoming Events

DDL 2026
SLAS
Bio IT
ELRIG Drug Discovery USA
Biotechnology Show 13.02.26
PFS & Injectable drug devices west coast

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

CDD Vault – 18.03.2025

Advertisement

Biopharma Group – 19th March 2025

Regulatory Impact Assessment is Obvious Next Target for GenAI, Experts Conclude 

When anything changes to a product’s make-up or manufacture, a whole chain of events is triggered, starting with an assessment of the regulatory impact in each regulatory jurisdiction, swiftly followed by required actions. Any delay or omission could be costly, so smart process automation offers attractive potential. Regulatory experts Preeya Beczek and ArisGlobal’s Agnes Cwienczek scope the opportunity. 

AI’s potential to transform speed and efficiency, and improve accuracy, has already been demonstrated across a number of Regulatory use cases. These early successes have instilled industry confidence in what the technology can do. Next in companies’ sights is regulatory impact assessment as part of overall product change control (the structured process to assess, document and implement changes to products). Intensifying pressure to bring medicines and updates to market quickly is galvanising Regulatory teams to work in more streamlined ways. Without recourse to artificial intelligence (AI), this is becoming increasingly unviable.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage